Elanco Animal Health Incorporated
Elanco Animal Health Incorporated (ELAN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
elan · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Elanco Animal Health Incorporated (ELAN) measures how much investors pay for each dollar of the company's trailing earnings. ELAN's current PE ratio of N/A is calculated by dividing its stock price of $23.43 by its TTM earnings per share of -$0.49.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%114.3x
MedianQ3 · 75%160.0x
Max
At N/A, ELAN's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Elanco Animal Health IncorporatedYou ELAN | $11.7B | N/A | — | -$0.49 |
 Align Technology, Inc. ALGN | $12.4B | 27.60x | +9.0% | $5.66 |
 Encompass Health Corporation EHC | $10.1B | 18.84x | -25.6% | $5.63 |
 The Ensign Group, Inc. ENSG | $9.3B | 29.02x | +14.6% | $6.00 |
 Neurocrine Biosciences, Inc. NBIX | $16.4B | 29.49x | +16.4% | $4.81 |
 Qiagen N.V. QGEN | $7.6B | 23.17x | -8.6% | $2.04 |
 Dr. Reddy's Laboratories Limited RDY | $11.1B | 23.89x | -5.7% | $54.16 |
Industry Average 6 peers with valid PE | — | 25.34x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.47 | — | |
2024-12-31 FY2024 | 17.70x | $0.68 | — | |
2023-12-31 FY2023 | — | $-2.50 | — | |
2022-12-31 FY2022 | — | $-0.16 | — | |
2021-12-31 FY2021 | — | $-0.99 | — | |
2020-12-31 FY2020 | — | $-1.27 | — | |
2019-12-31 FY2019 | 160.04x | $0.18 | +40.0% | |
2018-12-31 FY2018 | 114.35x | $0.28 | — | |
2017-12-31 FY2017 | — | $-0.87 | — | |
2016-12-31 FY2016 | — | $-0.13 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Elanco Animal Health Incorporated (ELAN) measures how much investors pay for each dollar of the company's trailing earnings. ELAN's current PE ratio of N/A is calculated by dividing its stock price of $23.43 by its TTM earnings per share of -$0.49.
Frequently asked questions
ELAN pe ratio · 6 questionsELAN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $23.43 and TTM EPS of -$0.49. Data sourced from Financial Modeling Prep via ELAN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Elanco Animal Health Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08